Kidney transplantation between donors and recipients with HIV is safe
NIH-funded study provides evidence on transplantation practice currently limited to research settings
2024-10-16
(Press-News.org) WHAT:
Kidney transplantation from deceased donors with HIV (HIV D+) to recipients with HIV (HIV R+) was safe and comparable to kidney transplantation from donors without HIV (HIV D-) in a multicenter observational study in the United States. The clinical outcomes observed were consistent with smaller pilot studies, but this National Institutes of Health (NIH)-funded clinical trial was the first statistically powered to demonstrate noninferiority, which means that an approach being studied is as good as standard clinical practice. The results were published today in the New England Journal of Medicine.
Kidney transplants offer a survival benefit to people with HIV and end-stage kidney disease, but an organ shortage limits access. In addition, people with HIV face a higher risk of death while on the organ waitlist and have lower access to transplants than people without HIV. To help address these disparities, the HIV Organ Policy Equity Act (HOPE) was implemented in 2015 and legalized transplants between donors and recipients with HIV. Currently, the HOPE Act limits this practice to research settings to carefully evaluate outcomes. These include post-transplant survival, post-transplant kidney function (also known as graft survival), and kidney rejection. Research studies also assess unique potential risks of this practice, such as acquiring a second, genetically distinct HIV strain from the donor that could affect the recipient’s HIV disease.
The present study enrolled 198 adults with HIV and end-stage kidney disease who received kidney transplants at 26 centers, comparing the outcomes of 99 study participants who had donors with HIV versus 99 whose donors did not have HIV. Transplants were completed between April 2018 and September 2021 and recipients were monitored subsequently for about three years.
The outcomes for overall survival, graft survival, and rejection events were similar between the two groups. After one year post-transplant, recipient survival was 94% in HIV D+/R+ and 95% in HIV D-/R+. At three years, recipient survival rates were 85% in HIV D+/R+ and 87% in HIV D-/R+. After one year post-transplant, graft survival was 93% in HIV D+/R+ and 90% HIV D-/R+. At three years post-transplant, graft survival rates were 84% in HIV D+/R+ and 80% in HIV D-/R+. Finally, at one year post-transplant, rejection incidence was 13% in HIV D+/R+ and 21% HIV D-/R+ and at three years, 13% in HIV D+/R+ versus 21% in HIV D-/R+. Rates of serious adverse events, surgical site infections, surgical/vascular complications, and cancer were also comparable between the two groups. One case of a recipient who may have acquired a second genetically distinct HIV strain from their donor was observed, but there were no notable clinical consequences.
Overall, the findings show kidney transplantation between donors and recipients with HIV was safe and noninferior to transplantation from donors without HIV. According to the authors, these findings offer evidence to support the expansion of the practice outside of research settings.
The study was led by the Johns Hopkins University School of Medicine, Baltimore, and funded by NIH’s National Institute of Allergy and Infectious Diseases (NIAID).
For more information about this trial, please visit ClinicalTrials.gov using the study identifier NCT03500315.
ARTICLE:
Durand et al. Safety of Kidney Transplantation from Donors with HIV under the HOPE Act. New England Journal of Medicine DOI: 10.1056/NEJMoa2403733 (2024).
WHO:
Andrew Redd, Ph.D., International Virology Unit, Head, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases.
CONTACT:
To schedule interviews, please contact NIAID News & Science Writing Branch, (301) 402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NIH...Turning Discovery Into Health®
END
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
2024-10-16
PROVIDENCE, R.I. [Brown University] — Biologists at Brown University have discovered how a neuropeptide hormone made in the gut of flies can control their lifespan.
The findings, published in PNAS, have implications for humans, too, the researchers say — especially as new diabetes and obesity medications based on gut hormones in the same family of the fly hormone are becoming more widespread.
For the past two decades, study author Marc Tatar, a professor of biology affiliated with the Center on the Biology of Aging at Brown University, has studied how the hormones insulin and insulin-like ...
2024-10-16
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, OCTOBER 16, 2024
MINNEAPOLIS – For people with ischemic stroke, treatment with the clot-busting drug tenecteplase is associated with a slightly higher likelihood of an excellent recovery and reduced disability three months later than the drug alteplase, according to a meta-analysis published in the October 16, 2024, online issue of Neurology®, the medical journal of the American Academy of Neurology. Researchers found that the likelihood of good recovery was similar ...
2024-10-16
Researchers at University of California San Diego School of Medicine found an FDA-approved drug used to treat breast cancer has the potential to be an effective therapeutic for a specific type of appendix cancer.
The clinical trial results, publishing in the October 16, 2024 online edition of the Journal of Clinical Oncology, showed the oral medication, known as palbociclib, stabilized tumor growth and reduced blood tumor marker levels in patients with peritoneal mucinous carcinomatosis (PMC). This form of cancer originates in the appendix and is often resistant to standard chemotherapy.
“Finding that a breast cancer drug is ...
2024-10-16
Research published in Nature Genetics on Oct.14, by Yale Cancer Center researchers at Yale School of Medicine, found a higher concentration of a specific kind of DNA — extrachromosomal or ecDNA — in more aggressive and advanced cancers that could mark them as targets for future therapies.
Using data available from The Cancer Genome Atlas, the International Cancer Genomics Consortium, the Hartwig Medical Foundation, and the Glioma Longitudinal Analysis Consortium, the researchers considered more than 8,000 tumor samples, divided between newly diagnosed untreated tumors and those that had been through previous treatments ...
2024-10-16
PHILADELPHIA (October 16, 2024) – J. Margo Brooks Carthon, PhD, RN, FAAN, the Tyson Family Endowed Term Chair for Gerontological Research; Professor of Nursing in the Department of Family and Community Health; and Associate Director of the Center for Health Outcomes and Policy Research, has been appointed the new Director of the Barbara Bates Center for the Study of the History of Nursing (Bates Center), the preeminent history of nursing research center and archive. The Bates Center amplifies the importance of the history of nursing and healthcare to the development of crafting effective health policies and strategies to improve health for all.
“The ...
2024-10-16
Scientists are developing advanced tools to understand and treat neurological symptoms such as brain fog associated with respiratory diseases like influenza. The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), awarded a three-year contract to researchers at the University of Rochester to develop a technology to model respiratory disease effects on the brain ...
2024-10-16
WASHINGTON, DC – As the nation continues to build a diverse, clean-energy workforce, the Department of Energy (DOE) today announced that applications are being accepted for the Summer 2025 term of two undergraduate internship programs.
The Office of Science Undergraduate Laboratory Internships (SULI) program and the Community College Internships (CCI) program are unique opportunities open to all current and recent college undergraduates. Interns will learn about science and technology careers, team science, networking, and gain the experience needed to transition from internship to employment.
The application deadline for both programs is January 8, 2025, ...
2024-10-16
UNIVERSITY PARK, Pa. — Several medications are available to treat high blood pressure, but more than 10 million Americans do not respond to the treatments, according to the American Heart Association. Using a bioelectronic device to deliver pulsed electricity to the body has proven to be a promising strategy to treat drug-resistant hypertension patients, according to Penn State researcher Tao Zhou, although he noted that its practical application in patient care has significant limitations.
Zhou, assistant professor of engineering science and mechanics and of biomedical engineering, received ...
2024-10-16
U.S. researchers have detected microplastic particles in air exhaled by wild bottlenose dolphins, suggesting that inhalation may be a relevant route of exposure to these potentially harmful contaminants. Miranda Dziobak of the College of Charleston in South Carolina, U.S., and colleagues present these findings in the open-access journal PLOS ONE on October 16, 2024.
Around the world, humans and numerous other animals are exposed to tiny particles of plastic contaminants known as microplastics. In humans and rodents, microplastic exposure has been linked to adverse health impacts, such as oxidative stress and inflammation. Ingestion ...
2024-10-16
A new paper published today in Science Advances exposes the global aquaculture sector’s growing dependence on wild fish. Despite industry claims to the contrary, these findings highlight how the growing appetite for expensive farmed salmon can leave coastal communities struggling to access affordable local fish like sardines and anchovies. Instead, these small pelagic fish are frequently caught, processed, and “reduced” to fishmeal and fish oil, almost all of which is used to feed farmed fish. These ‘reduction fisheries’ account for 26% of global ocean catch.
“As the aquaculture industry grows, so does its ...
LAST 30 PRESS RELEASES:
[Press-News.org] Kidney transplantation between donors and recipients with HIV is safe
NIH-funded study provides evidence on transplantation practice currently limited to research settings
